Network meta-analysis for deaths_(OS)

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

Evidence network for deaths_(OS)

1CheckMate 9LA, 20211ORIENT-11, 20201MYSTIC (D ; all population), 20201MYSTIC (DT ; all population), 20201EMPOWER lung1 (all population), 2021cemiplimab vs. durvalumab alone cemiplimab better 0.71 [0.53; 0.95]0.71 [0.53;0.95]cemiplimab vs. durvalumab alone cemiplimab better 0.71 [0.53; 0.95]cemiplimab vs. durvalumab plus tremelimumab cemiplimab better 0.72 [0.54; 0.97]0.72 [0.54;0.97]cemiplimab vs. durvalumab plus tremelimumab cemiplimab better 0.72 [0.54; 0.97]cemiplimab vs. nivolumab plus ipilimumab plus SoC 0.99 [0.70; 1.38]0.99 [0.70;1.38]cemiplimab vs. nivolumab plus ipilimumab plus SoC 0.99 [0.70; 1.38]cemiplimab vs. sintillimab plus SoC 1.12 [0.69; 1.82]1.12 [0.69;1.82]cemiplimab vs. sintillimab plus SoC 1.12 [0.69; 1.82]cemiplimab vs. Standard of Care (SoC) cemiplimab better 0.68 [0.53; 0.87]0.68 [0.53;0.87]cemiplimab vs. Standard of Care (SoC) cemiplimab better 0.68 [0.53; 0.87]durvalumab alone vs. cemiplimab cemiplimab better 1.41 [1.05; 1.90]1.41 [1.05;1.90]durvalumab alone vs. cemiplimab cemiplimab better 1.41 [1.05; 1.90]durvalumab alone vs. durvalumab plus tremelimumab 1.02 [0.81; 1.29]1.02 [0.81;1.29]durvalumab alone vs. durvalumab plus tremelimumab 1.02 [0.81; 1.29]durvalumab alone vs. nivolumab plus ipilimumab plus SoC nivolumab plus ipilimumab plus SoC better 1.39 [1.05; 1.85]1.39 [1.05;1.85]durvalumab alone vs. nivolumab plus ipilimumab plus SoC nivolumab plus ipilimumab plus SoC better 1.39 [1.05; 1.85]durvalumab alone vs. sintillimab plus SoC sintillimab plus SoC better 1.58 [1.00; 2.48]1.58 [1.00;2.48]durvalumab alone vs. sintillimab plus SoC sintillimab plus SoC better 1.58 [1.00; 2.48]durvalumab alone vs. Standard of Care (SoC) 0.96 [0.81; 1.13]0.96 [0.81;1.13]durvalumab alone vs. Standard of Care (SoC) 0.96 [0.81; 1.13]durvalumab plus tremelimumab vs. cemiplimab cemiplimab better 1.38 [1.03; 1.86]1.38 [1.03;1.86]durvalumab plus tremelimumab vs. cemiplimab cemiplimab better 1.38 [1.03; 1.86]durvalumab plus tremelimumab vs. durvalumab alone 0.98 [0.77; 1.24]0.98 [0.77;1.24]durvalumab plus tremelimumab vs. durvalumab alone 0.98 [0.77; 1.24]durvalumab plus tremelimumab vs. nivolumab plus ipilimumab plus SoC nivolumab plus ipilimumab plus SoC better 1.36 [1.03; 1.81]1.36 [1.03;1.81]durvalumab plus tremelimumab vs. nivolumab plus ipilimumab plus SoC nivolumab plus ipilimumab plus SoC better 1.36 [1.03; 1.81]durvalumab plus tremelimumab vs. sintillimab plus SoC 1.54 [0.98; 2.42]1.54 [0.98;2.42]durvalumab plus tremelimumab vs. sintillimab plus SoC 1.54 [0.98; 2.42]durvalumab plus tremelimumab vs. Standard of Care (SoC) 0.94 [0.80; 1.11]0.94 [0.80;1.11]durvalumab plus tremelimumab vs. Standard of Care (SoC) 0.94 [0.80; 1.11]nivolumab plus ipilimumab plus SoC vs. cemiplimab 1.01 [0.72; 1.42]1.01 [0.72;1.42]nivolumab plus ipilimumab plus SoC vs. cemiplimab 1.01 [0.72; 1.42]nivolumab plus ipilimumab plus SoC vs. durvalumab alone nivolumab plus ipilimumab plus SoC better 0.72 [0.54; 0.95]0.72 [0.54;0.95]nivolumab plus ipilimumab plus SoC vs. durvalumab alone nivolumab plus ipilimumab plus SoC better 0.72 [0.54; 0.95]nivolumab plus ipilimumab plus SoC vs. durvalumab plus tremelimumab nivolumab plus ipilimumab plus SoC better 0.73 [0.55; 0.97]0.73 [0.55;0.97]nivolumab plus ipilimumab plus SoC vs. durvalumab plus tremelimumab nivolumab plus ipilimumab plus SoC better 0.73 [0.55; 0.97]nivolumab plus ipilimumab plus SoC vs. sintillimab plus SoC 1.13 [0.70; 1.83]1.13 [0.70;1.83]nivolumab plus ipilimumab plus SoC vs. sintillimab plus SoC 1.13 [0.70; 1.83]nivolumab plus ipilimumab plus SoC vs. Standard of Care (SoC) nivolumab plus ipilimumab plus SoC better 0.69 [0.55; 0.87]0.69 [0.55;0.87]nivolumab plus ipilimumab plus SoC vs. Standard of Care (SoC) nivolumab plus ipilimumab plus SoC better 0.69 [0.55; 0.87]sintillimab plus SoC vs. cemiplimab 0.90 [0.55; 1.46]0.90 [0.55;1.46]sintillimab plus SoC vs. cemiplimab 0.90 [0.55; 1.46]sintillimab plus SoC vs. durvalumab alone sintillimab plus SoC better 0.63 [0.40; 1.00]0.63 [0.40;1.00]sintillimab plus SoC vs. durvalumab alone sintillimab plus SoC better 0.63 [0.40; 1.00]sintillimab plus SoC vs. durvalumab plus tremelimumab 0.65 [0.41; 1.02]0.65 [0.41;1.02]sintillimab plus SoC vs. durvalumab plus tremelimumab 0.65 [0.41; 1.02]sintillimab plus SoC vs. nivolumab plus ipilimumab plus SoC 0.88 [0.55; 1.42]0.88 [0.55;1.42]sintillimab plus SoC vs. nivolumab plus ipilimumab plus SoC 0.88 [0.55; 1.42]sintillimab plus SoC vs. Standard of Care (SoC) sintillimab plus SoC better 0.61 [0.40; 0.93]0.61 [0.40;0.93]sintillimab plus SoC vs. Standard of Care (SoC) sintillimab plus SoC better 0.61 [0.40; 0.93]Standard of Care (SoC) vs. cemiplimab cemiplimab better 1.47 [1.15; 1.88]1.47 [1.15;1.88]Standard of Care (SoC) vs. cemiplimab cemiplimab better 1.47 [1.15; 1.88]Standard of Care (SoC) vs. durvalumab alone 1.04 [0.88; 1.23]1.04 [0.88;1.23]Standard of Care (SoC) vs. durvalumab alone 1.04 [0.88; 1.23]Standard of Care (SoC) vs. durvalumab plus tremelimumab 1.06 [0.90; 1.26]1.06 [0.90;1.26]Standard of Care (SoC) vs. durvalumab plus tremelimumab 1.06 [0.90; 1.26]Standard of Care (SoC) vs. nivolumab plus ipilimumab plus SoC nivolumab plus ipilimumab plus SoC better 1.45 [1.15; 1.82]1.45 [1.15;1.82]Standard of Care (SoC) vs. nivolumab plus ipilimumab plus SoC nivolumab plus ipilimumab plus SoC better 1.45 [1.15; 1.82]Standard of Care (SoC) vs. sintillimab plus SoC sintillimab plus SoC better 1.64 [1.08; 2.50]1.64 [1.08;2.50]Standard of Care (SoC) vs. sintillimab plus SoC sintillimab plus SoC better 1.64 [1.08; 2.50]Standard of Care (SoC)placebo plus SoCnivolumab plus ipilimumab plus SoCsintillimab plus SoCdurvalumab alonedurvalumab plus tremelimumabcemiplimabdirect evidencenetwork meta-analysis
T vs. C Standard of Care (SoC)placebo plus SoCnivolumab plus ipilimumab plus SoCsintillimab plus SoCdurvalumab alonedurvalumab plus tremelimumabcemiplimab
Standard of Care (SoC)---NA1.45
1.15; 1.82		1.64
1.08; 2.50		1.04
0.88; 1.23		1.06
0.90; 1.26		1.47
1.15; 1.88
placebo plus SoCNA---NANANANANA
nivolumab plus ipilimumab plus SoC0.69
0.55; 0.87		NA---1.13
0.70; 1.83		0.72
0.54; 0.95		0.73
0.55; 0.97		1.01
0.72; 1.42
sintillimab plus SoC0.61
0.40; 0.93		NA0.88
0.55; 1.42		---0.63
0.40; 1.00		0.65
0.41; 1.02		0.90
0.55; 1.46
durvalumab alone0.96
0.81; 1.13		NA1.39
1.05; 1.85		1.58
1.00; 2.48		---1.02
0.81; 1.29		1.41
1.05; 1.90
durvalumab plus tremelimumab0.94
0.80; 1.11		NA1.36
1.03; 1.81		1.54
0.98; 2.42		0.98
0.77; 1.24		---1.38
1.03; 1.86
cemiplimab0.68
0.53; 0.87		NA0.99
0.70; 1.38		1.12
0.69; 1.82		0.71
0.53; 0.95		0.72
0.54; 0.97		---

pathologies: 36 - treatments: 1049 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons